Psoriasis is a chronic skin condition characterized by the rapid growth of skin cells, leading to the development of red, scaly patches on the skin. The condition is believed to have a genetic component, and understanding the genetic factors involved is crucial for both diagnosis and treatment. Various pharmaceutical and biotech companies are operating in this industry with an aim to develop effective diagnostic and treatment therapeutics for Psoriasis.
This company was founded on November 29th, 1984 by Heinrich Schulte and Jürgen Schumacher in Düsseldorf, Germany. It is a well-known provider of sample and assay technologies for pharmaceutical and academic research, molecular diagnostics, and applied testing.
QIAGEN plays a significant role by offering products and services that can aid in the diagnosis and research of psoriasis. Its developments support researchers in identifying and studying biomarkers associated with psoriasis. It also offers sample preparation technologies that allow for the extraction and purification of DNA and RNA from patient samples. This is essential for conducting genetic tests and molecular analyses related to psoriasis.
The company was established in 1991 by Walter Gilbert, Mark Skolnick, and Peter D Meldrum. Its headquarters are located in Salt Lake City, Utah, United States. It specializes in genetic testing and molecular diagnostics, with a particular focus on identifying genetic factors associated with various medical conditions.
With regard to Psoriasis, Myriad Genetics has made notable contributions to psoriasis disease diagnostics by offering genetic testing services and conducting research to identify genetic markers and biomarkers associated with the condition. These efforts enable early diagnosis, risk assessment, and personalized treatment strategies, advancing the understanding of the genetic basis of psoriasis and facilitating the development of precision medicine approaches for individuals affected by this chronic skin disorder.
The company was established on April 1st 1998 and its headquarters are located in San Diego, California, United States. It prime vision is to provide cutting-edge DNA sequencing and array-based technologies that enable researchers and healthcare professionals to explore and understand genetic variation, ultimately advancing genomics research, clinical diagnostics, and personalized medicine.
Illumina has been contributing to the psoriasis diagnostic landscape by empowering researchers and clinicians to investigate the genetic underpinnings of psoriasis. Their contributions help expand our knowledge of the disease and may lead to more precise diagnostic methods and personalized treatment options for individuals affected by psoriasis.
The pharma company was established by Gracias Saldanha in 1977. Its headquarters are located in Mumbai, India. It primarily focuses on the discovery, development, manufacturing, and marketing of a wide range of pharmaceutical products, including branded and generic formulations, active pharmaceutical ingredients (APIs), and specialty research-driven pharmaceuticals.
Glenmark has developed and marketed biologic therapies and dermatological products specifically designed to treat psoriasis. By offering biologics and dermatological treatments, participating in research, and supporting patients, Glenmark Pharmaceuticals plays a significant role in the ongoing effort to improve the lives of those living with psoriasis.
This pharmaceutical company was established in 1935 with its headquarters in Mumbai, India. It has an extensive portfolio of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients (APIs).
Cipla has been offering medications and therapies designed to manage the symptoms and improve the quality of life for individuals suffering from psoriasis. Its efforts to alleviate the symptoms of the disease, enhance the quality of life for affected individuals, and provide accessible healthcare solutions for those living with psoriasis.
Established on April 10th 2012, this pharmaceutical company has its headquarters in North Chicago, Illinois, United States. In terms of revenue, it has been ranked as the 6th largest biomedical companies worldwide. It emphasizes on research and development in various therapeutic areas, including immunology, oncology, neuroscience, virology, and more.
By offering biologic therapies, conducting research, and providing support for patients, AbbVie contributes significantly to the treatment and management of psoriasis. The company's efforts aim to alleviate the symptoms of the disease, enhance the quality of life for individuals affected by psoriasis, and advance the field of psoriasis treatment with innovative solutions.
In the field of psoriasis disease, several key players, including pharmaceutical companies like AbbVie, Cipla, and biotechnology firms such as Myriad Genetics, Illumina, and QIAGEN, have made significant contributions to diagnostics, treatment, and research. These companies have been instrumental in advancing our understanding of the genetic and molecular basis of psoriasis, developing innovative therapies, and providing support to patients. Together, they are solidifying their industry foothold and actively working to improve the lives of individuals affected by this chronic skin condition through precision diagnostics and effective treatment options.